[Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Recombinant human erythropoietin (EPO) was administered i.v. to anaemic patients (pts) on hemodialysis in doses from 40 to 120/IU/kg 3 times a week. 20 out of 21 pts showed an increase in hemoglobin (Hb) level above 11 g/dl after 8-12 weeks. Maintenance doses to keep Hb value about 10 g/dl varied from 2 X 40 IU/kg to 3 X 40 IU/kg per week (subcutaneous). EPO improved the well-being and physical condition in all of pts. Six pts developed rise in blood pressure and most an increase in predialysis serum potassium and urea levels during first 16 weeks of treatment.
Boratyńska
M
M
Katedry i Kliniki Nefrologii Akademii Medycznej we Wrocławiu.
Szewczyk
Z
Z
Szepietowski
T
T
Czyz
W
W
Cybulski
K
K
Bogucki
J
J
Szczepański
J
J
D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011995:Recombination, Genetic; D006435:Renal Dialysis; D013997:Time Factors
D006454:Hemoglobins; D004921:Erythropoietin
Ludzka rekombinowana erytropoetyna w leczeniu niedokrwistości u chorych długotrwale hemodializowanych.